At Advamed 2013, industry leaders met and discussed how startups and innovation can beat the odds without much chance of gaining venture capital at an extremely early stage. Here are realistic options for medical device companies looking to fundraise early rounds without venture. 1. Raise enough for each round. Remember that truism from Mark Twain […]
Ultragenyx is developing a sialic acid replacement therapy for treatment of the rare, progressive neuromuscular disease hereditary inclusion body myopathy that causes muscles to waste away.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
They came from all parts of North Carolina’s Research Triangle, and several of them from far beyond, to hear the story of how a small biotechnology company developed a breakthrough cancer treatment, blazed a path for future development of personalized medicine treatments and was purchased in a deal valued at $935 million — the biggest […]
Early stage life science companies still developing their technologies can fall into a gap: too expensive to be supported by more grants or angel investments yet not far enough along to secure venture capital interest. In the worst economy in generations, their funding challenges are more pronounced. But the first quarter saw several companies in […]
A new migraine treatment from CoLucid Pharmaceuticals is approaching phase 3 clinical trials and the North Carolina-based company is raising $6.5 million in a bridge round of financing to get it there.
CeNeRx BioPharma has raised a $13 million Series C round of financing that will fund phase 2 clinical trials of its antidepressant drug candidate.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
David Anderson says the road to developing an artificial spinal disc nucleus is littered with “spectacular failures.” But that doesn’t deter Anderson or his company, Philadelphia-based Gentis, from trying to be the first to get a disc nucleus replacement device for the lower spine on the U.S. market. The nucleus pulposus is the jelly-like substance […]
Pappas expects to use the fund to invest in 12 to 15 companies over the next several years.